20-F: Altamira Therapeutics Repositions for RNA Delivery, Reports Annual Results in Form 20-F

Altamira Therapeutics focuses on RNA delivery technology, divesting non-core assets and reporting its annual results in a Form 20-F filing.

Summary

• Altamira Therapeutics is strategically repositioning to focus on RNA delivery technology, particularly OligoPhore and SemaPhore platforms.
• The company divested a 51% stake in Altamira Medica AG (Bentrio business) and intends to divest or partner its AM-125 program.
• Key programs include AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development.
• The company reported a net loss of CHF 3.9 million for 2023, compared to a net loss of CHF 26.5 million in 2022, which included a one-time write-off of CHF 12.4 million.
• The company's cash and cash equivalents as of December 31, 2023, were CHF 0.6 million, with an expected additional cash need of CHF 6.5 to 7.5 million in 2024.
• The company acknowledges substantial doubt about its ability to continue as a going concern without additional funding.
• The company is working to remediate material weaknesses in internal control over financial reporting.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is strategically repositioning and has promising technology, it faces significant financial challenges and risks, including a going concern uncertainty and material weaknesses in internal controls.

Positives

• Strategic repositioning towards RNA delivery technology may unlock new avenues for treating intractable diseases.
• Divestiture of non-core assets allows for greater focus and resource allocation to RNA delivery programs.
• Preclinical development of AM-401 and AM-411 shows promise for addressing unmet medical needs.
• The company significantly lowered its operating expenses in 2023.
• The company regained compliance with Nasdaq's minimum shareholders equity requirement on November 21, 2023.

Negatives

• The company has a limited operating history and a history of operating losses.
• The company has substantial doubt about its ability to continue as a going concern.
• The company needs substantial additional funding to continue its research and development programs.
• The company's internal control over financial reporting was not effective as of December 31, 2023 and 2022, due to material weaknesses.
• The company depends entirely on the success of OligoPhore, SemaPhore, AM-401 and AM-411 which are still in preclinical development.

Risks

• The company may be unable to raise additional capital when needed.
• The company's development programs may be unsuccessful.
• The company may face intense competition from other businesses.
• The company relies on third parties to conduct certain of its nonclinical studies and perform other tasks for us.
• The price of the company's common shares may be volatile and may fluctuate due to factors beyond its control.
• The company's common shares may be involuntarily delisted from trading on The Nasdaq Capital Market if it fails to comply with the continued listing requirements.
• The company may be subject to claims challenging the inventorship of its patents and other intellectual property.

Future Outlook

The company expects to continue to incur significant operating losses in the future as it continues its research and development efforts for its RNA delivery platforms and product candidates. The company expects its total additional cash need in 2024 to be in the range of CHF 6.5 to 7.5 million.

Industry Context

The company is operating in the competitive biopharmaceutical industry, facing competition from various businesses, including large pharmaceutical companies, academic institutions, and research institutions. The company's success depends on its ability to discover product candidates, develop and to out-license them successfully.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document does mention that the global market for RNA therapeutics (RNAi and ASOs) reached $4.9 billion in 2021 and is expected to grow to $25.1 billion in 2030.
• The document also mentions that the global market for mRNA therapeutics should grow from $46.7 billion in 2021 to $101.3 billion by 2026.
• These numbers can be used as a benchmark to compare the company's performance to the industry.

Corporate Governance

Related Party Transactions

• Gremaud GmbH provides the Chief Financial Officer for the Company.
• Thomas Meyer, the Company's CEO, lent CHF 200,000 to the Company under the September 9, 2022 Loan Agreement.
• From December 8, 2022 to March 8, 2023, Mr. Meyer's spouse provided one of the Company's subsidiaries with a short-term loan of CHF 100,000.00.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures or restructuring.
• The company's ability to develop and commercialize new therapies could impact patients with unmet medical needs.
• The company's financial stability could affect its relationships with suppliers and partners.

Next Steps

• Advance AM-401 and AM-411 programs through preclinical studies with the objective of filing for an IND in 2025.
• Leverage OligoPhore / SemaPhore platform through partnering.
• Divest or partner remaining legacy assets in 2024.
• Review and discuss plans for IND-enabling preclinical studies with the FDA in the context of a Pre-IND meeting.
• Conduct a Phase 1 clinical trial in patients with KRAS driven cancer either on our own or through a partner from the biopharmaceutical industry.

Key Dates

Keywords

RNA delivery, OligoPhore, SemaPhore, AM-401, AM-411, Altamira Therapeutics, Financial Results, Going Concern, Reverse Share Split, Bentrio, Divestiture, Biopharmaceutical, Keyzilen, Sonsuvi